Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
Academic Journal
The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin therapy is more effective than placebo in controlling glycemic level, glucagon-like peptide (GLP-1) are associated with weight loss and dipeptidyl peptidase (DDP4) inhibitors are linked with weight gain.


Related Articles

  • COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes. Vella, Adrian // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are...

  • Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Riddle, Matthew C.; Drucker, Daniel J. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p435 

    Discusses a study which summarized several limitations in the treatment of type 2 diabetes and describes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Barriers to...

  • Glucagon-like peptide agonists. Gadsby, Roger // Practice Nurse;4/9/2010, Vol. 39 Issue 7, p30 

    The article discusses glucagon-like peptide 1 (GLP-1) and its potential role in the treatment of type 2 diabetes. The levels of GLP-1 in people with diabetes are reduced in response to a meal and it is easily broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Clinical tests reveal that...

  • Gliptins: A New Class of Oral Antidiabetic Agents. SESHADRI, K. G.; KIRUBHA, M. H. B. // Indian Journal of Pharmaceutical Sciences;2009, Vol. 71 Issue 6, p608 

    India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for...

  • Nonlinear Increase in GLP-1 Levels in Response to DPP-IV Inhibition in Healthy Adult Subjects. Dai, Haiqinq; Gustavson, Stephanie M.; Calle, Roberto A.; Hirshberg, Boaz // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Dipeptidyl Peptidase IV (DPP-IV) inhibitors represent a new promising target for the treatment of T2DM. The aim of this study was to investigate the effects of DPP-IV inhibition by PF-00734200, a potent competitive DPP-IV inhibitor, on the dynamics of plasma in healthy adult subjects. In a...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • A gut-heart connection in cardiometabolic regulation. Buglioni, Alessia; Burnett, John C // Nature Medicine;May2013, Vol. 19 Issue 5, p534 

    The article offers information on the study of Kim and colleagues which examines the link between glucagon-like peptide-1 (GLP-1) release from the cardiac hormone atrial natriuretic peptide and gut. It states that glycemia in patients with type 2 diabetes were controlled using GLP-1 receptor...

  • Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Dave, Darshan J. // Journal of Pharmacology & Pharmacotherapeutics;Oct2011, Vol. 2 Issue 4, p230 

    Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin defi ciency or resistance. Management starts with single oral antidiabetic drug (OAD) but eventually switch over to combination therapy because of progressive ?-cell dysfunction. Hypoglycemia, weight gain, and...

  • Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Mann, Katherine V.; Raskin, Philip // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;2014, Vol. 7, p229 

    Background: This article reviews the clinical efficacy, safety, and patient outcomes literature on the first once weekly treatment for type 2 diabetes mellitus (T2DM), exenatide extended-release (ER). Methods: Relevant literature on exenatide ER and T2DM was identified through PubMed database...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics